These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36722447)

  • 21. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
    Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
    Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
    Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
    Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use.
    Le Collen L; Delemer B; Poitou C; Vaxillaire M; Toussaint B; Dechaume A; Badreddine A; Boissel M; Derhourhi M; Clément K; Petit JM; Mau-Them FT; Bruel AL; Thauvin-Robinet C; Saveanu A; Cherifi BG; Le Beyec-Le Bihan J; Froguel P; Bonnefond A
    Genet Med; 2023 Jul; 25(7):100857. PubMed ID: 37092539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
    Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
    Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome.
    Lazareva J; Sisley SR; Brady SM; Smith ACM; Elsea SH; Pomeroy JJ; Roth CL; Sprague JE; Wabitsch M; Garrison J; Yanovski JA
    Obes Res Clin Pract; 2024; 18(4):301-307. PubMed ID: 38987029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.
    Ferraz Barbosa B; Aquino de Moraes FC; Bordignon Barbosa C; Palavicini Santos PTK; Pereira da Silva I; Araujo Alves da Silva B; Cristine Marques Barros J; Rodríguez Burbano RM; Pereira Carneiro Dos Santos N; Rodrigues Fernandes M
    J Pers Med; 2023 Oct; 13(10):. PubMed ID: 37888071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
    Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
    N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of non-syndromic early-onset child and adolescent obese patients in terms of
    Nalbantoğlu Ö; Hazan F; Acar S; Gürsoy S; Özkan B
    J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1041-1050. PubMed ID: 35801948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of Heterozygous Variants in Genes of the Leptin-Melanocortin Pathway in Severe Obesity.
    Courbage S; Poitou C; Le Beyec-Le Bihan J; Karsenty A; Lemale J; Pelloux V; Lacorte JM; Carel JC; Lecomte N; Storey C; De Filippo G; Coupaye M; Oppert JM; Tounian P; Clément K; Dubern B
    J Clin Endocrinol Metab; 2021 Sep; 106(10):2991-3006. PubMed ID: 34097736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
    Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
    Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two Cases With an Early Presented Proopiomelanocortin Deficiency-A Long-Term Follow-Up and Systematic Literature Review.
    Gregoric N; Groselj U; Bratina N; Debeljak M; Zerjav Tansek M; Suput Omladic J; Kovac J; Battelino T; Kotnik P; Avbelj Stefanija M
    Front Endocrinol (Lausanne); 2021; 12():689387. PubMed ID: 34177811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes.
    Poitou C; Puder L; Dubern B; Krabusch P; Genser L; Wiegand S; Verkindt H; Köhn A; von Schwartzenberg RJ; Flück C; Pattou F; Laville M; Kühnen P; Clément K
    Surg Obes Relat Dis; 2021 Aug; 17(8):1449-1456. PubMed ID: 34083135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
    Ryan DH
    J Obes Metab Syndr; 2021 Sep; 30(3):196-208. PubMed ID: 34518444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
    Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
    Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterozygous Genetic Variants in Autosomal Recessive Genes of the Leptin-Melanocortin Signalling Pathway Are Associated With the Development of Childhood Obesity.
    Šket R; Kotnik P; Bizjan BJ; Kocen V; Mlinarič M; Tesovnik T; Debeljak M; Battelino T; Kovač J
    Front Endocrinol (Lausanne); 2022; 13():832911. PubMed ID: 35574020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel LEPR mutations in Pakistani families with morbid childhood obesity.
    Niazi RK; Gjesing AP; Hollensted M; Have CT; Grarup N; Pedersen O; Ullah A; Shahid G; Ahmad W; Gul A; Hansen T
    BMC Med Genet; 2018 Nov; 19(1):199. PubMed ID: 30442103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Monogenic and Syndromic Obesity.
    Han JC; Rasmussen MC; Forte AR; Schrage SB; Zafar SK; Haqq AM
    Gastroenterol Clin North Am; 2023 Dec; 52(4):733-750. PubMed ID: 37919024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Narrative of a Patient with Leptin Receptor Deficiency: Personalized Medicine for a Rare Genetic Obesity Disorder.
    Welling MS; Kleinendorst L; van Haelst MM; van den Akker ELT
    Obes Facts; 2023; 16(5):514-518. PubMed ID: 37393902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tracing the effect of the melanocortin-4 receptor pathway in obesity: study design and methodology of the TEMPO registry.
    Eneli I; Xu J; Webster M; McCagg A; Van Der Ploeg L; Garfield AS; Estrada E
    Appl Clin Genet; 2019; 12():87-93. PubMed ID: 31239751
    [No Abstract]   [Full Text] [Related]  

  • 40. Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study.
    Folon L; Baron M; Toussaint B; Vaillant E; Boissel M; Scherrer V; Loiselle H; Leloire A; Badreddine A; Balkau B; Charpentier G; Franc S; Marre M; Aboulouard S; Salzet M; Canouil M; Derhourhi M; Froguel P; Bonnefond A
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):182-190. PubMed ID: 36822744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.